{'output': [['Shire', 'COMP', 'Cut', '2020 Revenue Target', 'ECON_INDICATOR'], ['Shire', 'COMP', 'Prepare', 'Spin-off of ADHD drugs', 'PRODUCT'], ['Shire', 'COMP', 'Operate_In', 'Pharmaceutical Group', 'ORG'], ['Shire', 'COMP', 'Acquire', 'Baxalta', 'COMP'], ['Shire', 'COMP', 'Have', 'Revenue of $15 billion', 'ECON_INDICATOR'], ['Shire', 'COMP', 'Face', 'Increased Generic Competition', 'CONCEPT'], ['Shire', 'COMP', 'Face', 'New Drugs from Rivals', 'CONCEPT'], ['Shire', 'COMP', 'Drop', 'Revenue Target of $20 billion by 2020', 'ECON_INDICATOR'], ['Shire', 'COMP', 'Set', 'New Revenue Target of $17-18 billion by 2020', 'ECON_INDICATOR'], ['Shire', 'COMP', 'Face', 'Additional Competition in Hematology', 'SECTOR'], ['Shire', 'COMP', 'Have', 'Immunology Franchise', 'SECTOR'], ['Shire', 'COMP', 'Consider', 'Spinning off Hyperactivity Drugs', 'PRODUCT'], ['Shire', 'COMP', 'Evaluate', 'Merits of an Independent Listing for Each of the Two Divisions', 'CONCEPT'], ['Hematology', 'SECTOR', 'Threaten', 'Some of Shireâ€™s Products', 'PRODUCT'], ['U.S. Regulators', 'ORG/GOV', 'Approve', 'Generic Competitor to Lialda', 'PRODUCT'], ['Shire', 'COMP', 'Leader', 'Neuroscience', 'SECTOR'], ['Shire', 'COMP', 'Acquire', 'Adderall-owner Richwood Pharmaceutical', 'COMP'], ['Shire', 'COMP', 'Consider', 'Spinning off Hyperactivity Drugs into a Standalone Group', 'CONCEPT'], ['Analysts', 'ORG', 'Say', 'Standalone Group could be Worth as much as $8.5 billion', 'ECON_INDICATOR']]}